Pancreatic safety of sitagliptin in the TECOS study

Diabetes Care

Volumn 40, Issue 2, 2017, Pages 164-170

  Buse, John B ^a   Bethel, M Angelyn ^b   Green, Jennifer B ^c   Stevens, Susanna R ^c   Lokhnygina, Yuliya ^c   Aschner, Pablo ^d   Grado, Carlos Raffo ^e   Tankova, Tsvetalina ^f   Wainstein, Julio ^g   Josse, Robert ^h   Lachin, John M ⁱ   Engel, Samuel S ^j   Patel, Keyur ^k   Peterson, Eric D ^c   Holman, Rury R ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^e Centre Region CINVEC   (Chile)

^f MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^g WOLFSON MEDICAL CENTER   (Israel)

^h ST MICHAEL'S HOSPITAL   (Canada)

ⁱ GEORGE WASHINGTON UNIVERSITY   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; ADULT; CANCER RISK; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATALITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ACUTE DISEASE; AGED; CHEMICALLY INDUCED; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 85011700235     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2780     Document Type: Conference Paper

References (12)

1. Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013;42:1227-1237
2. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
3. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 58:1604-1615
4. Aston-Mourney K, Subramanian SL, Zraika S, et al. One year of sitagliptin treatment protects against islet amyloid-associated b-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 2013;305:E475-E484
5. Chadwick KD, Fletcher AM, ParrulaMC, et al. Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. Diabetes 2014;63: 1303-1314
6. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 2015;14:505-524
7. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 2014;16:1247-1256
8. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
9. Scirica BM, BhattDL, Braunwald E, et al.; SAVORTIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326
10. Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care 2014;37: 2435-2441
11. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
12. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-989.e7